Intermediate Endpoints Predict Breast Cancer Survival

Data suggest that intermediate clinical endpoints can serve as surrogate endpoints for overall survival in patients with early-stage breast cancer receiving adjuvant therapy.

Related Keywords

Udine ,Friuli Venezia Giulia ,Italy ,Aviano ,Italian ,Eva Blondeaux ,Lorenzo Gerratana ,University Of Udine ,Italian Breast Group ,Department Of Medicine ,Department Of Medical Oncology ,Policlinico San Martino ,Medical Oncology ,Breast Cancer ,Alignant Breast Neoplasm ,Breast Carcinoma ,Breast ,Mammary Gland ,Cancer ,Alignant Neoplasia ,Arcinoma ,Alignant Neoplasm ,Adjuvant Chemotherapy ,Genomics Genomic Medicine ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Healthcare Technology ,Medical Technology ,Adjuvant Therapy ,Clinical Research ,Clinical Trials ,